top of page

info@prapela.com
833-772-7352

833-prapela

Research & Grants

With hundreds of infants and their parents contributing to past and current studies, we are building the evidence to support regulatory clearance for several newborn medical conditions.

Clinical Research

"Use of SVS Device to Improve Outcomes for Neonatal Opioid Withdrawal Syndrome" is an ongoing study led by Tufts Medical Center with support from 5 other hospitals. The research is made possible by a grant from the National Institute of Drug Abuse (NIDA).

"Efficacy of a Vibrating Crib Mattress to Reduce Pharmacological Treatment in Opioid-Exposed Newborns," published in JAMA Pediatrics, shows the effectiveness of Prapela's stimulation in reducing morphine and hospital length of stay in opioid-exposed babies.

"Vibrotactile Stimulation: A non-pharmacological intervention for opioid-exposed newborns," provides early evidence of the ability of Prapela's technology to improve relaxation, breathing, and heart rate in opioid-exposed newborns. 

"Stochastic Resonance Effects on Apnea, Bradycardia, and Oxygenation: A Randomized Controlled Trial," published in Pediatrics, the Journal of the American Academy of Pediatrics, demonstrated the effectiveness of Prapela's stimulation on apneic events and associated low oxygenation and slow heart rates.

"Stabilizing immature breathing patterns of preterm infants using stochastic mechanosensory stimulation" provides early evidence that Prapela's stimulation is so gentle that it does not interrupt sleep cycles in preterm newborns.

Apnea of Prematurity - A new randomized clinical trial documenting the effectiveness of Prapela's stimulation in reducing apneic episodes in preterm newborns is recruiting patients at Tufts Medical Center and the University of Alabama at Birmingham. This pivotal train is funded by a,  grant from the National Institutes of Health, Blueprint Neuroscience program (award #U44DA059390.

Grants

"Prapela SVS: A cost-effective stochastic vibrotactile stimulation device to improve the clinical course of infants with neonatal abstinence syndrome." This Phase I SBIR grant from NIH/NIDA demonstrated the technical and commercial feasibility of converting a clinically tested technology into a medical device.

"Prapela SVS: A cost-effective stochastic vibrotactile stimulation device to improve the clinical course of infants with neonatal abstinence syndrome." Our Phase II SBIR grant from NIH/NIDA is an active project to establish the safety, efficacy, and acceptability of our SVS hospital bassinet pad as a low-cost medical device for use in the hospital to improve the clinical course of newborns with neonatal opioid withdrawal syndrome (NOWS).

"Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity." This Fast-Track SBIR grant from the NIH Blueprint program is to complete the development of and establish the safety, efficacy, and clinical risk/benefit of our hospital incubator pad that will provide a complementary treatment and the first improvement in the clinical management of apnea of prematurity in over 20 years.

Thanks for submitting!

iStock-676570626 reduced.jpg

Get in Touch

© 2025 by Prapela, Inc. Powered and secured by Wix

bottom of page